Company Description
VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease.
It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.
In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905.
The company has collaboration and license agreements with Brii Biosciences Limited; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome.
The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016.
VBI Vaccines Inc. is based in Cambridge, Massachusetts.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 131 |
| CEO | Jeffery R. Baxter FCMA |
Contact Details
Address: 160 Second Street, Cambridge Cambridge, Massachusetts 02142 United States | |
| Phone | 617-830-3031 |
| Website | vbivaccines.com |
Stock Details
| Ticker Symbol | VBIV |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000764195 |
| CUSIP Number | 91822J103 |
| ISIN Number | CA91822J2020 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jeffery R. Baxter FCMA | President, Chief Executive Officer and Director |
| Dr. David Evander Anderson | Chief Scientific Officer |
| Dr. Francisco Diaz-Mitoma FRCPC, M.D., Ph.D. | Chief Medical Officer |
| Nell Beattie | Chief Financial Officer, Head of Corporate Development and Director |
| Nicole Anderson | Director of Corporate Communications and Investor Relations |
| Athena Kartsaklis | Senior Vice President of Finance, Chief Compliance Officer and Principal Financial Officer |
| Avi Mazaltov | Global Head of Manufacturing and GM of SciVac |
| Misha Nossov | Senior Vice President of Global Commercial Supply Strategy and Head of Europe |
| T. Adam Buckley | Senior Vice President of Business Development |
| John Robert Dillman | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Apr 16, 2024 | 10-K | Annual Report |
| Apr 16, 2024 | 8-K | Current Report |
| Apr 11, 2024 | 8-K | Current Report |
| Apr 11, 2024 | 424B5 | Filing |
| Apr 3, 2024 | 8-K | Current Report |
| Apr 2, 2024 | 8-K | Current Report |
| Mar 28, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Feb 14, 2024 | 8-K | Current Report |
| Feb 6, 2024 | 8-K | Current Report |